Clinical trial
Prospective Pilot Study of the Clinical Efficacy and Safety of the Method for Preventing a Graft-versus-host Disease Through the Agency of Using the Combination of Post-transplantation Cyclophosphamide with Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis After Hematopoietic Stem Cell Transplantation from an Unrelated or Haploidentic Donor
NCT06756152 is registered in ClinicalTrials.gov with Federal Research Institute of Pediatric Hematology, Oncology and Immunology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective Pilot Study of the Clinical Efficacy and Safety of the Method for Preventing a Graft-versus-host Disease Through the Agency of Using the Combination of Post-transplantation Cyclophosphamide with Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis After Hematopoietic Stem Cell Transplantation from an Unrelated or Haploidentic Donor
- Lead sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- Phase
- Phase 2/3
- Overall status
- Recruiting
- Start date
- July 10, 2024
- Completion date
- October 10, 2026
- Enrollment
- 50 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
acute lymphoblastic leukemia, bilinear leukemia, biphenotypic acute leukemia, malignant lymphoma, non-hodgkin, myeloblastic leukemia, myelodysplastic syndrome